As a mother and health executive, I know that when it comes to babies, trust and safety are everything. At Biotherapeutics, we don’t just make products, we craft solutions backed by rigorous science and compassion.
That’s why Labinic™ holds a special place in my heart and on our production line.
What Is Labinic™?
Labinic™ is a multistrain liquid probiotic formulated for infants from birth. A single 0.2 ml dose delivers 2 billion live CFUs, using a vegan-friendly, gentle formulation that bypasses allergens and refrigeration.
It includes three scientifically validated strains:
- Lactobacillus acidophilus NCFM
- Bifidobacterium bifidum Bb‑06
- Bifidobacterium infantis Bi‑26
These strains mirror the flora of breastfed infants, supporting digestion, feed tolerance, and immune system development.
Clinically Validated — Evidence You Can Trust
Multiple peer-reviewed studies, randomized controlled trials (RCTs), andmeta-analyses validate Labinic™’s efficacy in neonatal care:
- PeerJ 2016 Meta‑Analysis:
Involving over 5,000 preterm infants, this systematic review showed probiotic use (including Labinic™ strains) halved the risk of severe necrotizing enterocolitis (NEC) and reduced all-cause mortality (RR for NEC 0.53, mortality RR 0.79) jamanetwork.com+5biofloratech.com+5pmc.ncbi.nlm.nih.gov+5en.wikipedia.org+8peerj.com+8peerj.com+8. - Randomized Controlled Trial in South Africa:
A double-blind RCT using Labinic™ found zero NEC cases in the probiotic group versus 5 cases in placebo, plus a significant reduction in feeding intolerance (p < 0.001) pmc.ncbi.nlm.nih.gov. - Multi‑Trial Meta‑Analyses:
Broader umbrella reviews confirm that multi-strain probiotics reduce NEC and mortality by ~50%, especially formulations like Labinic™ pmc.ncbi.nlm.nih.gov+15bmcgastroenterol.biomedcentral.com+15sciencedirect.com+15. - Feeding Tolerance Meta-Analysis (2022):
Nine RCTs (~1,244 preterm infants) reported probiotics significantly shortened time to full feeds, improved weight gain, reduced hospital stay, and lowered feeding intolerance by ~62% mdpi.com+1pmc.ncbi.nlm.nih.gov+1en.wikipedia.org+4tp.amegroups.org+4pmc.ncbi.nlm.nih.gov+4. - Real‑World Clinical Outcomes (Stockholm 2022):
A cohort study of very preterm infants showed probiotic use shortened time to full feeds (6.6 vs 7.2 days) and decreased antibiotic days — supporting Labinic™-like formulations tp.amegroups.orgmdpi.com.
Trusted by Parents and Professionals
- Over 3 million doses administered safely biofloratech.com
- No dairy, gluten, animal products, or allergens — 100% vegan
- Shelf-stable, convenient for both homes and NICUs
- Clinician-approved, included in multiple neonatal unit guidelines biofloratech.com
Manufactured to Pharmaceutical Standards
Every batch of Labinic™ is produced under pharmaceutical-grade conditions, ensuring:
- High bacterial viability
- Consistency across batches
- Long shelf life at room temperature
- Strict quality control
My Personal Commitment
As COO of Biotherapeutics — and a mother — I take pride in delivering a product that’s effective, evidence-based, and safe. Labinic™ represents our promise: to give vulnerable infants the strongest start possible, supported by real-world outcomes and robust clinical research.
When it comes to your baby’s health, nothing less than excellence will do.
Nazrana R Sanker, MBA
Chief Operating Officer, Biotherapeutics
Mother | Wellness Advocate | Evidence-Based Leader
